TY - JOUR
T1 - Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy
AU - Matsuda, Satoru
AU - Tsubosa, Yasuhiro
AU - Niihara, Masahiro
AU - Sato, Hiroshi
AU - Takebayashi, Katsushi
AU - Kawamorita, Keisuke
AU - Mori, Keita
AU - Tsushima, Takahiro
AU - Yokota, Tomoya
AU - Ogawa, Hirofumi
AU - Onozawa, Yusuke
AU - Yasui, Hirofumi
AU - Takeuchi, Hiroya
AU - Kitagawa, Yuko
N1 - Funding Information:
Yuko Kitagawa has the following financial relationships to disclose: research funding from Kyowa Hakko Kirin Co., Ltd, Bristol-Myers Co., Ltd, Nippon Kayaku Co., Ltd, Pfizer Co., Ltd, and Yakult Honsha Co., Ltd.
Publisher Copyright:
© 2015, Society of Surgical Oncology.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 % in the TTE group, and complete response rate was 68 % in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 %; dCRT 49.8 %; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 %; dCRT 40 %; p = 0.003).Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.
AB - Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 % in the TTE group, and complete response rate was 68 % in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 %; dCRT 49.8 %; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 %; dCRT 40 %; p = 0.003).Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.
UR - http://www.scopus.com/inward/record.url?scp=84939998090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939998090&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-4337-7
DO - 10.1245/s10434-014-4337-7
M3 - Article
C2 - 25564176
AN - SCOPUS:84939998090
SN - 1068-9265
VL - 22
SP - 1866
EP - 1873
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -